OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Annual report and financial statements

For the year ended 31 December 2025

Contents

5 Introduction: Winds of change

18 Looking ahead to 2026 20 22

Our strategy 2030: an overview

Goal 2: Shape the future of the health and care system to ensure the best care for all Goal 3: Build new approaches to testing and innovation that could transform health and care

23

24

26 Financial review and statements

3

Winds of change

Introduction from the Chief Executive and Chair

The Health Foundation’s mission – to build a healthier UK – remains unchanged. Indeed, progressing our mission has never been more vital.

The health of the UK’s population is stalling and inequalities in health are wide and growing. This plus the ageing of the population, and the considerable risk factors injuring health, add up to an avoidable burden of ill health now and into the future.

This situation hobbles human development and flourishing, is a drag on prosperity and creates immense pressure on the NHS due to rising demand. At the same time, because the UK economy is not growing as fast as desired, this creates fiscal challenges that constrain budgets for the public services and infrastructure needed to support good health. The changeable nature of the political environment also makes stable long-term policymaking harder.

In these times, the Foundation – with its independent voice and endowment – is uniquely placed to help understand problems and find solutions, with the stability and freedom to think longer term. But while foundations are a relatively stable feature in the public landscape, we are not immune to change, nor should we be. 2025 saw the Q community move to its new home at the NHS Alliance, where it will build on the past decade’s work supporting quality improvement in health across the UK and Ireland. This promising move fulfils our original aim of embedding Q in the NHS.

In 2025 there were other significant changes within the Foundation alongside the development of our new strategy, which launched in April 2026. Our strategy 2030 reflects our desire to be bolder in setting out solutions to the challenges we face – and to use our independence, resources and partnerships to do it. Throughout this 5-year strategy, we will put health and inequalities at the heart of policy and decision making, and work to shape the future of the health and care system to ensure the best care is available for all. This will include investing in new approaches to testing innovations that could transform health and care for the future. (See Looking ahead to 2026 for more on what to expect.)

5

In 2025, however, we continued to be guided by three strategic priorities:

In each area we undertook a range of activities, from grant-making, research and fellowships, to collaborating with stakeholders and working in partnership.

Generating robust evidence and insight through our research and analysis remains central to our work. In 2025 we published several major outputs, allowing us to reach audiences, gain media traction and influence policy and practice. The year saw the launch of our NHS Productivity Commission, in recognition of the vital need to improve productivity in the health service, ensure the NHS is financially sustainable and that it provides taxpayers value for money. The Commission’s first major report – From diagnosis to delivery – provides a framework for accelerating productivity in the NHS, and followed over 120 submissions from key organisations, NHS staff and service users. The Commission will set out a series of policy options and final recommendations in 2026.

July saw the arrival of government’s long-awaited 10-Year Health Plan – a dizzying array of proposals spanning NHS structures, services, staffing and more. The Foundation influenced the plan’s content through events, media commentary, blogs and several briefings, alongside extensive engagement with senior stakeholders. Our impact was clear: widespread media coverage on launch day; multiple citations in the plan; demand for our expertise on its commitments after publication, such as a blueprint for tech adoption beyond procurement and advisory roles shaping the legislation underpinning the reforms.

In fact, the transformative potential of tech is where many hopes continue to be pinned. In May, our analysis highlighted the multi-billion pound cost of digitising the NHS and adult social care, helping to inform the thinking behind the £10bn committed for digitisation in the Spending Review, with a senior

6

official telling us it had ‘helped to shift thinking at the Treasury’. In October, our second AI in the NHS Summit convened NHS and industry leaders to explore and share best practice in testing and spreading impactful AI solutions. Planning for our next summit is already well underway.

In addition, we achieved impact through collaboration with other organisations. For example, Health Equals continued to champion cross-sector action on health inequality, with its cross-sector coalition of member organisations more than doubling to 105. Its bold public campaigns, including the award-winning ‘Hazmat Loungewear’ campaign on the health risks from damp, cold and mould, helped to drive 1.2 million visits to the Health Equals website, and earned over 200 pieces of national and regional media coverage across the year.

Our Action for healthier working lives publication was the final report of the Commission of the same name. This set out clear recommendations on how to improve the health of the working-age population in work, which continues to influence national policy.

Our achievements in 2025, which we are immensely proud of, are due to the hard work and commitment of staff, governors and the people we work with across health and care. Together, we look forward to making progress in 2026 as we enter our new strategic period – always for the benefit of the health of the UK population and, in particular, the most vulnerable in society.

Dr Jennifer Dixon Chief Executive

Sir David Behan* Chair

*Sir David Behan took over as Chair from Sir Hugh Taylor in August 2025.

7

2025: Year in review

Improving people’s health and reducing inequalities

Health is our most precious asset. It is shaped by the work we do, the income we earn, the education we receive and the places, communities and families we live in.

Improving health and reducing inequalities requires a whole-society approach. We want decision makers across all parts of society to understand and fulfil their potential contribution to building a healthy nation.

Key highlights

Influencing the public health grant through our long-term

work : In 2025/26, the grant was increased in real terms for the first time in over a decade. The Foundation’s analysis on historical cuts became the ‘go to’, following its 2018 publication

and subsequent updates. This supported several high-profile media moments, funding options presented to the Department of Health and Social Care (DHSC) and sector advocacy.

Putting health at the heart of local growth : Our £2.1m

Economies for Healthier Lives programme and the growth and reform network research have increased our profile among practitioners and supported policy engagement. Local government webinars showcasing these learnings reached well over 1,000 people.

Measuring prevention spend : Our funding of the Chartered Institute of Public Finance and Accountancy (CIPFA) to develop a framework to classify, account and track local government prevention spend has had high engagement from local authorities. It was adopted and used by the Scottish government and the Future Generations Commissioner for Wales.

10

Advocating to #MakeHealthEqual : Health Equals – the campaigning coalition to reduce health inequalities founded and supported by the Foundation – more than doubled its membership from 47 to 105 organisations and its parliamentary champions network grew to 112 MPs and peers. Bold public campaigns included the ‘Hazmat Loungewear’ campaign on health risks from damp, cold and mould, which won best PR campaign at the Roxhill 2026 Media Awards.

Case study

Embedding recommendations from the Commission for Healthier Working Lives

The independent Commission for Healthier Working Lives (CHWL) was established by the Health Foundation to build consensus on the action needed by government and employers to meet the UK’s working-age health challenge.

The commission has shaped government thinking on work, health and welfare, influencing the national debate and policy towards preventing health-related exits from the labour market.

Our analysis was quoted in the media and in parliament by the secretary of state, including two direct recommendations made by CHWL: a new unemployment insurance benefit and a ‘right to try’ work for benefit claimants. Meanwhile, the commission’s focus on the role of employers heavily influenced the recommendations of the Keep Britain Working review.

Impact has been enabled by strong relationships with senior officials, expert convening and influential analysis, building on past analysis that had established the Health Foundation as a voice on health and employment policy. CHWL has elevated the Health Foundation’s profile, shaped external research and contributed to widespread uptake of its framing across think tanks, local authorities, sector bodies and the media.

11

Supporting radical innovation and improvement in health and care services

Innovation and improvement are more important than ever to ensure that health and care services meet people’s needs now and in the future.

We want to give policymakers, system leaders, service providers, health care staff, service users and the public the insights, practical resources and opportunities needed to support the far-reaching shifts needed in health and care over the coming decade.

Key highlights

Revealing the multi-billion pound cost of digitising the NHS

and adult social care : Our major analysis was the first publicly available evidence-based estimate of its kind. It directly informed thinking behind the £10bn committed for NHS digitisation in the 2025 Spending Review. One senior official told us it had ‘helped to shift thinking at the Treasury’.

Building our reputation on AI : Our second annual AI in the NHS Summit had over 1,500 attendees and viewers, and brought together speakers including the then Minister for Health Innovation, Zubir Ahmed MP. Feedback was highly positive,

including that the event had helped to catalyse much-needed conversations across government.

Influencing progress on new care models : Our Adopting

Innovation programme funded an early adopter of the ‘Brazilian’ Community Health and Wellbeing Worker model – a community-led approach designed to bridge the gap between clinical health care and local neighbourhoods – helping to build up the evidence base for its effectiveness. This was instrumental in the government’s commitment to the model in the 10-Year Health Plan: the programme in Cornwall and academic evaluation of our funded project was cited by Wes Streeting to justify the focus on this approach.

12

Growing Q’s impact : The network has now exceeded 6,000 members, delivered its first paid-for board development offer and secured funding to support the NHS in Wales to implement quality management systems. This bodes well for Q in its new home at NHS Alliance, which it transferred to in November 2025.

Case study

Convening NHS leaders to catalyse action

The Foundation’s expertise has been in demand, with multiple requests from senior policy and NHS stakeholders for input to help develop their thinking. This has provided excellent opportunities for influencing and generated positive feedback.

Activities included:

13

Providing evidence and analysis to improve health and care policy

We want to see policy decisions on health and social care informed by the best available evidence and analysis, to improve the health system now and for the future.

Key highlights

Launching the NHS Productivity Commission : The

commission’s first report, From diagnosis to delivery , included expert elicitation findings on the annual NHS productivity target that sparked conversation, media pick up and resulted in the report being shared widely. This approach meant that our public-facing call for evidence received over 120 submissions from key organisations, NHS staff and service users. Having established a credible foundation for the commission’s work, its final report and recommendations are due in 2026.

Shaping social care reform : We influenced Fair Pay Agreement (FPA) policy through working group involvement, engagement with sector stakeholders and our consultation response. The government’s policy impact assessment cited our work. We also informed Spending Review discussions regarding FPA funding by presenting our analyses to the Treasury and DHSC.

Assessing the government’s first year : We independently assessed government progress on its agenda with our flagship report Labour’s first year , using our analytical capability to hold government to account. As part of this suite of work,

our briefing exploring what the 10-Year Health Plan should look like ahead of its publication, was our most popular of the year.

14

Growing international collaborations and networks : We welcomed the seventh cohort of Sciana fellows to our European leadership programme focused on cross-cutting challenges facing health and care in Europe. We also published a mix of

work comparing international health systems to identify lessons for policy in the UK – including a major new report with OECD.

Case study

Influencing policy through public perceptions research

Our ongoing partnership with Ipsos provided timely insight into public attitudes towards the NHS and social care, shaping the debate.

Our polling was widely picked up by media and stakeholders, shared directly with the 10-Year Health Plan team, quoted by government in relation to the GP contract and prompted discussion on the public’s priorities, including on access to GPs.

We amplified this work through high profile events at party conferences. We held panel events with Ipsos and the Resolution Foundation and participated in nine further fringe events. We also secured panel participation from key political commentators, ministers and party spokespeople.

15

Work to improve the Foundation

In 2025, we undertook our Future Foundation programme to ensure the organisation’s operating model, people, culture, systems and processes will enable us to deliver the requirements of our new 5-year strategy.

16

Key developments

We continue to work to make the Foundation an inclusive and diverse organisation where employees are valued – in July 2025, this meant we formally recognised UNISON as our trade union.

2025 was challenging as to improve our internal ways of working, we embarked on a restructure to align future work around our two new strategic pillars of health care and health and inequalities. This meant that we started collective consultation on the proposals in November 2025, with individual consultation starting in 2026. While we worked to minimise compulsory redundancies by offering attractive voluntary redundancy levels, such a process is never easy for the individuals and the organisation.

We also continued to progress with our EDI strategy, though some elements of delivery were inevitably disrupted by the consultation and change process.

We also continued to focus on improvements to our systems and processes – with a focus on the approach to managing our governance and decision making, people and funding and procurement.

Alongside the development of the new strategy we refreshed our values: Impact, Evidence, Integrity and Collaboration – helping us to stay aligned with our mission, reflect who we are and what we believe, and they will guide all that we do.

17

Looking ahead to 2026 18

The nation’s health is increasingly frayed and unequal – and health and care services are under pressure, with too many people going without the care and support they need.

Launched in April 2026, Our strategy 2030 reflects our desire to be

bolder in setting out solutions to the challenges we face – and to use our independence, resources and partnerships to do it.

2026 will mark a transitional year for the Foundation, following a period of change within the organisation and as we embark on our new 5-year strategy.

19

Our strategy 2030: an overview

Mission

----- Start of picture text -----
Build new
approaches to
testing innovation
that could transform
health and care
----- End of picture text -----

Goals

Delivery

----- Start of picture text -----
Delivery Thematic programmes
Generating Testing Engagement, Networks and
Approaches research and practical convening and long-term
analysis solutions partnerships capability
Our values underpin everything we do:
Impact Evidence Integrity Collaboration
----- End of picture text -----

20

Our goals

Our work to 2030 will focus on responding to the major challenges facing health and care in the UK: stalling health and widening health inequalities, widespread pressures in the health and social care system, and the need to harness innovation and new technology to maximise public benefit.

By 2030, we want to:

  1. put health and inequalities at the heart of decision making

  2. shape the future of the health and care system to ensure the best care for all

  3. build new approaches to testing innovation that could transform health and care.

Achieving the first two goals will be the core of the Health Foundation’s work. Our third goal, on testing innovation, is newer for the Health Foundation, more uncertain, and comes with challenge and complexity. These are risks that we are uniquely positioned to take.

Across all three goals, we will explore new partnerships that could help us have a stronger impact.

Cross-cutting issues

  1. Health inequalities in the UK are deep and persistent. As well as promoting cross-sector action on health inequalities, our equity, diversity and inclusion strategy strengthens our commitment to understanding and reducing inequalities across all our work and becoming a more diverse and inclusive organisation.

  2. Environmental sustainability

will also cut across our work. The World Health Organization (WHO) has defined climate change as the greatest health threat of the 21st century. The NHS is responsible for around 40% of public sector carbon emissions and has legally binding targets to achieve net zero. Meeting these targets will depend on changes to how resources are allocated, targets are set, local providers are regulated, services are delivered and more.

Thematic programmes

We will organise the delivery of our work through six thematic programmes: reform and neighbourhood health; health and the economy; public health led prevention; performance and resources; cross sector action; and technology and AI.

We will also consider broader, cross-cutting issues for health systems and society across our work.

21

Goal 1: Put health and inequalities at the heart of decision making

The biggest factors that shape health and inequalities lie outside health care. Yet governments repeatedly prioritise the NHS over broader investments and policies to help people live healthier lives.

how to make progress on key risk factors, such as air pollution and obesity. We will support regional and local leaders to apply insights, directing our support where it will make most difference.

We have established ourselves as an authoritative voice on the society-wide action needed to improve health and reduce health inequalities. We will continue to provide evidence and analysis on the factors that shape these and on the need for coordinated action across government.

• We will build support for cross-sector action on health inequalities and undertake new work on developing a whole-government strategy for health. We will also continue to support Health Equals, the campaigning coalition to reduce health inequalities.

Relevant thematic programmes:

Health and the economy; Reform and neighbourhood health; Public health-led prevention; Cross-sector action on health inequalities; Technology and AI

22

Goal 2: Shape the future of the health and care system to ensure the best care for all

Equitable access to high-quality health services is essential to protect and improve the nation’s health. Yet the NHS and social care are under major strain, and many people go without care they need.

The Foundation has built a strong reputation for analysing and informing NHS and social care policy. We will continue to use evidence and analysis to shape the future direction of the health and care system – doing more to identify promising solutions to the challenges it faces. We will also analyse overall policy and performance of the health and care system in England, highlighting key areas in need of improvement and reform.

• We will independently assess and inform the overall direction of health and social care policy in England. We will learn from countries facing similar challenges and bring policymakers and others together to discuss the biggest questions for the future. We will also look squarely at the politics of the NHS and its future – with a focus on the policy changes needed to boost productivity. This includes the launch of the final report of the NHS Productivity Commission in 2026.

Relevant thematic programmes:

Reform and neighbourhood health; Public health-led prevention; Performance and resources; Technology and AI

23

Goal 3: Build new approaches to testing and innovation that could transform health and care

Innovation in health care delivery, often using AI and other adaptive technologies, is spreading rapidly across the NHS. But these innovations are too often adopted without good evidence on impact. And existing evaluation methods can be slow, expensive and lack quality. This poses major challenges for the NHS and policy.

Our third goal, on testing innovation, is newer for the Health Foundation, more uncertain and comes with challenge and complexity. These are risks that we are uniquely positioned to take.

• We have already started to test and develop these approaches. For instance, we are evaluating the use of ambient voice technology (AVT) in the NHS with The Healthcare Improvement Studies (THIS) Institute, a Foundation-backed initiative based at the University of Cambridge working to strengthen the evidence base for improvement and innovation in health care. The focus of this goal is likely to expand over the course of the strategy – for instance, by exploring wider health interventions.

24

Financial review and statements

26 Financial review and statements

Legal and administrative information

Governors

Sir Hugh Taylor (Chair) (to 31 July 2025) Sir David Behan (from 9 July 2025 and Chair from 1 August 2025) Katie Blacklock Dawn Edge Kim Graham (from 16 August 2025) Eric Gregory (to 30 June 2025) Ravi Gurumurthy (to 31 August 2025) Loraine Hawkins Ruth Hussey Paul Najsarek Karen Reid (from 12 August 2025) Roland Sinker David Smart Rosalind Smyth (to 17 July 2025) Rachel Sylvester Stian Westlake (from 12 August 2025)

Charity number

286967

Investment fund managers

See Appendix

Company number 01714937

Registered office

8 Salisbury Square London EC4Y 8AP

Custodian and performance measurement

Northern Trust 50 Bank Street Canary Wharf London E14 5NT

Investment advisers

External auditor

UHY Hacker Young Quadrant House 4 Thomas More Square London E1W 1YW

Solicitors

Bates Wells 10 Queen Street Place London EC4R 1BE

Cambridge Associates Limited 62 Buckingham Gate London SW1E 6AJ

Gallagher (Administration & Investment) Limited The Walbrook Building 25 Walbrook London EC4N 8AW

Financial review and statements 27

Charitable activities in 2025

Our charitable expenditure

As well as adapting and improving what we do, we’re also concentrating on how we do it. We take our role as an independent charitable organisation seriously, and we continue to do lots to improve our day-to-day activities. During 2025, we reviewed our cost base and target operating mode to make sure we are financially sustainable and our work is aligned to the new 2026-30 strategy, this culminated in an organisational restructure which started collective consultation in November 2025 and the full effects of which will be seen in 2026.

In 2025 our charitable expenditure is made up of:

Our charitable expenditure of £56.6m is illustrated in the chart below; the outer circle shows the split by strategic priority, with the inner circle split as described above.

28 Financial review and statements

Figure 1: Charitable expenditure in 2025

37[%] 36[%] 27[%] Grant funding Direct Support and of activities costs governance costs £21.2m £20.2m £15.1m

5[%] Cross-cutting strategic activities £2.6m

16[%] Improving people’s health and reducing 57[%] inequalities Supporting radical £9.1m innovation and improvement in health and care services £32.2m

22[%] Providing evidence and analysis to improve health and care policy £12.7m

Financial review and statements 29

2025 was the third and final year delivering our 3-year strategy, therefore this is the last year charitable spend will be allocated to our three 2023-5 strategic priorities. Our charitable expenditure of £56.5m compares to £50.4m in 2024, the key movements were:

and care services spending was £5.7m more than prior year, driven by the cost allocation as the £5.6m increased commitment to Q relating to the transfer as described above. This was offset by large commitments in 2025 including £1.6m in the Tech for Better Care programme, £1.3m IMPACT centre, £1.2m intermediate care grant. Despite these changes this remained the largest area of spend and therefore cost allocation increased overall costs.

spending was £5.0m less than in 2024. In 2024 we awarded £1.8m to support the Health Equals campaign and the £0.7m contribution to the UK Prevention Research Partnership, with nothing equivalent in 2025 there were associated reductions in cost allocation reducing costs further.

care policy spending was £7.5m higher driven by the 2025 recommitment of £3.2m to the University of York supply economics research unit increasing the cost allocation.

Further information can be found in note 7 to the accounts.

Our income used for charitable activities

Our charitable activities are mainly funded by our endowment. In 2025, we received £21.0m investment income and transferred £33.8m of capital from the endowment, in line with our expenditure policy.

We received restricted income of £0.4m (2024: £1.7m) primarily for Q, an initiative joint-funded with NHS Improvement. The Q initiative started in April 2015 and is part of our substantial long-term investments to develop and support initiatives designed to build improvement and innovation capability, which moved to its new home in NHS Alliance (formerly NHS Confederation) in November 2025 to support Q’s ongoing journey to sustainable and further strengthen the links to the NHS.

30 Financial review and statements

Our policies

Expenditure policy

In our investment section we set out the spending formula for the Foundation's drawdowns from the endowment. This was revised in 2025 to a formula based on the Yale model combining inflation adjusted current spending and investment performance to provide a more robust framework, greater certainty for the Foundation and a longer-term planning horizon. The Foundation also introduced financial constraints for non-charitable spend to ensure they remain reasonable and proportionate.

Grant-making policy

The Foundation sets out specific entitlement criteria for each programme at its launch. These criteria vary from programme to programme and are made available on our website. Applications are assessed against these criteria and grants made considering funds available and the quality of applications.

The period for which grants are awarded depends on the programme, but typically last between 1 and 4 years, with the exception of THIS Institute. Grants are monitored regularly and appropriate progress reports are required from recipients.

Reserves policy

The Foundation holds an expendable endowment fund, which was created following the sale of PPP Healthcare Group (PPP) to Guardian Royal Exchange Group in 1998. It is the Foundation’s policy to operate as a perpetual body and, in line with this policy, the governors seek to manage the Foundation’s business, and in particular its investment returns and expenditure, to maintain the real value of this expendable endowment fund while providing the necessary income to fund the Foundation’s ongoing charitable activities.

Within the above overall policy, governors are at any time able to use endowment capital to fund charity expenditure. Accordingly, governors have determined that it is not necessary for the charity to hold reserves by way of separate unrestricted funds. Capital from the endowment equal to the excess of the Foundation’s expenditure over its generated unrestricted income is applied as income each year such that at the year end the unrestricted fund balance is nil.

Financial review and statements 31

Our investments

Investment policy and strategy

The board of governors have committed to run the Foundation as a permanent institution so the endowment, while technically expendable, is treated as if in perpetuity to support the operations of the Foundation over the very long term. Therefore, apart for the need to retain a degree of near-term liquidity in order to fund the nearer term operations, the emphasis is on achieving a substantial long-term real rate of return of 4% over inflation, measured by the Consumer Price Index. The aim is for the real value of the endowment to be preserved over the long term allowing for 4% per annum distributions to fund operations.

At the beginning of 2025, a revised methodology used to calculate annual expenditure was approved by the governors on the recommendation of the Investment Committee. The existing method of calculating distributions did not allow for any inflationary increase in the operational expenditure of the Foundation and did not allow for sufficient long-term smoothing of the value of the endowment. The formula used by Yale University and adopted by many endowments over many decades was considered most appropriate to accommodate for these factors. Specifically, the Yale endowment spending policy as we are applying it in the Foundation is a weighted calculation of 30% of the endowment value 2 years prior and 70% of prior year spending, adjusted by prior year inflation. The methodology uses an agreed spending rate of 4% to provide the right balance between long-term sustainability and short-term needs of the Foundation.

The endowment has a structured investment process consisting of two primary features:

32 Financial review and statements

Nine investment beliefs developed by the governors were updated in March 2025. These provide a framework for accountability across all investmentrelated activities and decision making.

  1. Governance We maintain a high level of governance to manage a large endowment, investing across a set of globally diversified assets.

  2. Investment objective Our long-term return objective is set at CPI+4%, supporting the long-term sustainability of the endowment.

  3. Achieving risk-adjusted returns Alongside monetary assets, we invest in liquid growth assets in the belief that over the long-term they will produce sufficient returns above inflation to meet our target return. Over the long-term an allocation to illiquid growth assets will be additive to those returns.

  4. Inflation dynamics We recognise that inflation poses a significant risk to the endowment achieving the real return target over the long-term.

  5. Managing capital loss: risk tolerance and diversification By embedding a risk tolerance of 20% 1-year 95 Value at Risk, we aim to manage short-term drawdown risk while pursuing long-term growth objectives.

  6. Liquidity requirements We ensure that at least 2 years of operating budget is maintained in cash and high-quality short-dated bonds.

  7. Active management Financial markets are not always efficient, presenting opportunities for skilled active investment managers to achieve returns that exceed those of the broader market.

  8. Responsible investment Operating through a dual lens allows us to jointly consider financial return and responsible ownership.

  9. Investing for net positive outcomes Long-term investments in strategies that demonstrate measurable and net positive outcomes across nature-based and health systems can generate risk-adjusted market returns and help us deliver impact against our sustainability goals.

The Investment Committee reviews performance and the investment risk management framework, in addition to reviewing the long-term investment strategy and monitoring progress on its implementation. We are long term investors and, as such, while we monitor the strategic asset allocation quarterly, we do not carry out short-term tactical readjustments to asset class weightings.

Financial review and statements 33

The in-house investment team manage the endowment on a day-to-day basis, implementing strategic asset allocation and monitoring all performance, risk metrics and portfolio holdings. Gallagher is the investment advisor for the endowment and provide advice on strategic asset allocation, investments, and responsible investment practices. Cambridge Associates provides investment management services for the Victoria Fund and investment advice on alternative asset classes.

Our approach to responsible investment

The governors recognise that business activities that cannot be sustained environmentally or socially will naturally give rise to risks, and these may be financially material. However, companies that operate responsibly across environmental, social and governance factors produce superior long-term returns, benefiting both investors and society through sustainable practices. To ensure the long-term sustainability of the endowment’s investments, and consistent with the duty to act in the best financial interests of the Foundation, the governors seek to avoid those risks and capitalise on long-term opportunities through a good understanding of how material sustainability issues impact the endowment.

Responsible investment approaches are integrated across all investment-related activities guided by two sustainability ambitions:

Four responsible investment guiding principles have been developed, and updated in 2025, to provide the endowment's investment strategy with an overarching framework to strengthen responsible investing and stewardship credentials and seek to ensure the right balance between delivering the financial return target required to fund the Foundation, alignment with the Foundation’s mission and values, and an understanding of the reputational risk associated with both actions and inactions.

34 Financial review and statements

In practice, our approach to responsible investment involves the effective integration of environmental, social, governance (ESG) factors into decision-making, and stewardship activities, such as engagement, collaboration and voting practices. The objective is to promote long-term sustainable value creation through the oversight of managers and companies owned to guide better real-world sustainable business outcomes. We require all our investment managers to demonstrate leadership in ESG integration and reporting and recommend they adopt at least one of the following guidelines; the UK Stewardship Code or the UN Principles of Responsible Investment.

We do not invest directly in tobacco stocks. We also closely monitor our investment in funds and should a stock appear that could be seen as a conflict of interest for the mission of the Foundation, we would negatively screen these stocks from the endowment. However, where possible, we adopt a formal approach to positive engagement where conflict of interest might arise. Where there are issues related to reputational risk, these reside with the governors.

The Health Foundation is a member of the Charities Responsible Investment Network and maintains a dialogue with a number of investor coalitions to promote best practice.

Financial review and statements 35

Investment returns

Our long-term goal for our endowment investments are set out in the Investment policy and strategy earlier in this report.

In 2025 the endowment returned 7.1%, underperforming the target performance of 7.4% (CPI+4%). During the year, public equity markets performed strongly, with gains being led by countries outside of the US, in a reversal of the prior trend of US out-performance that has been experienced for a number of years. Private equity and venture capital lagged public equity markets. representing an ongoing moderation in performance from private equity since the exceptional gains that were made in the period up until the end of 2021.

Global markets have continued to experience volatility in 2026, driven by ongoing geopolitical tension and conflict in the Middle East. However, equity markets have continued to make gains despite elevated uncertainty, with US equity markets being supported by significant levels of capital expenditure and investor enthusiasm regarding AI, which is expected to support growth in the months ahead. However, consensus expectations for inflation are rising across much of the global economy and the prospect of tighter monetary policy may act as an increasing constraint on this positive sentiment in the future.

Figure 2 shows the change in the value of the investments. In 2025, the value of the investments increased by £38m, from £1,242m to £1,280m.

Strategic Asset Allocation

The last review of the strategic asset allocation was undertaken in 2024, in accordance with the scheduled 3-year review cycle. Following this review, the decision was taken to withdraw from hedge fund assets and increase allocations to ‘near cash’ assets (high quality UK gilts) and initiate an allocation to investing in alternative impact investment funds which clearly demonstrate net positive outcomes across society and nature-based systems. Implementation of these changes began towards the end of 2024 and continued in 2025, hence the updated targets. See Figure 3.

The flexibility exists to increase the liquidity (cash) buffer within the endowment to ensure that the spending needs of the Foundation can be

36 Financial review and statements

met. We are holding cash and fixed incomes assets to cover at least 2 years of expenditure.

Early in 2025 global financial markets experienced volatility following the announcement of US trade tariffs. Endowment public equity valuations were impacted during this period, however in line with expectations due to the diversified nature of the investments. By the end of April 2025 asset valuations had somewhat recovered. The Investment Committee held an extraordinary meeting in April to review the endowment valuation and strategic asset allocation. The Investment Committee agreed to increase cash and high-quality short-dated bonds to 3 years of expenditure to ensure the endowment maintains enough liquidity to fund the Foundation’s plans for the foreseeable future, which was maintained throughout 2025 and is subject to ongoing review. It remains appropriate for the endowment to tolerate periods of market volatility and maintain an allocation to growth assets, such as public equity and private equity strategies, to provide the required level of sustainable returns, CPI+4%.

As at the end of 2025, the portfolio was underweight compared to its current target allocation to equities and impact investments. This was offset by an overweight position in fixed income and alternative assets. However, the current target allocations represent an interim target, with the current equity and alternatives allocations already aligned with their future final target allocations The remaining cash & fixed income overweight positions and Impact under-allocation are expected to move closer to their targets through gradual readjustments over time.

Figure 2: Investment values as at 31 December 2025

----- Start of picture text -----
£1,400m
£1,280m
£1,231m £1,177m £1,196m £1,242m
£1,200m £1,076m [£1,125m]
£1,039m
£966m £980m
£1,000m
£800m
£600m
£400m
£200m
£m
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
----- End of picture text -----

Financial review and statements 37

Figure 3: Comparison of the asset allocation 31 December 2025 to 2024 and target asset allocation*

----- Start of picture text -----
Listed equities Alternative assets Fixed income strategies
Infrastructure Property Impact Cash and near cash
1%
2025 51% 20% 14% 6% 4% 4%
2%
Target 55% 18% 12% 5% 4% 4%
2024 53% 25% 7% 6% 5% 4%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
----- End of picture text -----

*The full Target Strategic Asset Allocation (SAA) was agreed end-2024 for implementation in 2026. The Interim Target SAA per the graph acts as a guide to inform future investment allocations, where deviations from this target can occur due to adjustments in market valuations and revised allocations due to the market environment. The difference in the Alternative assets’ allocation is due to a change in the future allocation, notably the removal of Hedge Funds.

The total cost of managing our investments was £13.2m (2024: £16.9m). The decrease was driven by our decisions to move away from hedge funds and increase our passive allocations, and further details can be found in note 6.

Subsidiary companies

At the end of 2025, the Foundation had three subsidiary undertakings Medtrust Innovations Limited (Medtrust), the Victoria Fund LP Incorporated (Victoria Fund) and THIS Labs Ltd (THIS Labs).

Medtrust is wholly owned by the Foundation as a mission-related investment engaged in the exploitation of intellectual property rights. In March 2011, Medtrust acquired 50% of the intellectual property rights of BMJ Quality & Safety, a journal published by the BMJ Publishing Group Limited. At 31 December 2025, Medtrust had fixed assets of £0.5m (2024: £0.5m). In the year, Medtrust generated an operating profit of £0.2m (2024: £0.2m).

The Victoria Fund was formed in February 2010 as a vehicle to invest in a combination of hedge funds and private equity. The Health Foundation, as the limited partner, is entitled to all investment returns less a priority share by the

38 Financial review and statements

general partner. As at 31 December 2025, the Victoria Fund had investment assets of £357m (2024: £392m) and the value of its net assets was £356m (2024: £395m). The net decrease in value for 2025 was £39m (2024: £41m) was mainly due to the sale of hedge funds and transfers of cash to the charity totalling £53m (2024: £63m), adjusting for this Victoria Fund made a £15m gain in 2025 (2024: £22m).

The Health Foundation’s third subsidiary, THIS Labs, was set up to enable improvement and innovation in the health and care sector through online collaboration with an initial investment of £4m to achieve these goals made in 2023 and a further £1.5m Credit Loan Note was paid in 2025. As at the end of the year the value of the net assets of THIS Labs was £1.4m (2023: £3.3m). The future plans for the company continued to be discussed by both the THIS Labs Board and the Foundation Board in early 2026, which resulted in revisions to the strategy and structure of the business and have significantly reduced the cost base. Please note that THIS labs was renamed in January 2026 to Thiscovery Ltd.

Financial review and statements 39

Streamlined energy and carbon reporting

The Health Foundation is reporting energy and carbon emissions in compliance with The Companies (Directors’ Report) and Limited Liability Partnerships (Energy and Carbon Report) Regulations 2018. The conversion factors used in the report are taken from 2025 Government guidance on the Streamlined Energy and Carbon Reporting (SECR) regime. We have restated 2024 information due our landlord’s revision of how they provide our gas consumption information; we rely on our suppliers to supply accurate and timely information in order to complete this report.

The energy the Foundation consumed reduced slightly to 649,124 Kwh in 2025 (2024 restated: 673,368 Kwh) and CO2 emissions decreased to an estimated 128.91 tonnes (2024 restated: 148.11 tonnes). Our intensity ratio is 0.053 tonne per square metre of our office space (2024 restated: 0.061 tonne per square metre).

Electricity and gas – office

During 2025, our office electric energy consumption equated to 70.71 tCO2e (2024: 91.56 tCO2e). This has been impacted by a 15% decrease on prior year in the conversion rate from kWh to tCO2e as our electricity consumption has decreased from 446,772 kWh to 404,325 kWh (10%). Our office gas energy consumption increased from 226,596 kWh to 244,799 KWh which is 44.70 tCO2e (2024 restated: 41.36 tCO2e). Electricity costs are partly metered and partly apportioned while gas costs form part of the service charge, apportioned by the landlord on the floor space occupied by the Foundation, which equates to 2,415 square metres.

Travel

During 2025 we travelled across the UK and in Europe to deliver and support our activities. Travel journeys paid for directly by the Foundation equated to 144,344 miles (2024: 143,970 miles) or 13.50 tCO2e (2024: 15.19 tCO2e). Our CO2 emissions were directly impacted by fewer long haul flights in 2025. Travel to and from Foundation events by external participants and attendees are not included in these calculations for both years.

40 Financial review and statements

Commitments and reporting

Sustainability is an important part of the Foundation’s 2030 strategy and of how we think about our long-term impact. We have committed to making our endowment net zero by 2035 and, during 2025, continued to build the foundations for a broader sustainability strategy and action plan across our wider operations.

We welcome the stronger emphasis that Charity SORP 2026 places on Environmental, Social and Governance (ESG) reporting. This provides a valuable framework for showing not only how we are working to reduce our environmental impact, but also how we are contributing socially and promoting strong, responsible governance across the Foundation.

In the years ahead, we look forward to sharing more about our progress and the steps we are taking across all three areas of ESG.

----- Start of picture text -----
2025 carbon reporting figures Mileage Consumption Carbon
kwh emission
tCO2e
Scope 2
Health Foundation office – gas 244,799 44.70
Health Foundation office – electricity 404,325 70.71
Scope 3
– –
Employee mileage personal cars
Travel – taxis 1,121 0.31
Travel – public transport 91,267 4.95
Travel – air 51,956 8.24
Total gross emissions in tonnes CO2e 144,344 649,124 128.91
Intensity ratio: tonnes CO2e per sqm 0.053
2024 restated carbon reporting figures Mileage Consumption Carbon
kwh emission
tCO2e
Scope 2
Health Foundation office – gas 226,596 41.36
Health Foundation office – electricity 446,772 91.56
Scope 3
Employee mileage personal cars 300 0.05
Travel – taxis 1,530 0.23
Travel – public transport 87,540 4.57
Travel – air 54,600 10.34
Total gross emissions in tonnes CO2e 143,970 673,368 148.11
Intensity ratio: tonnes CO2e per sqm 0.061
----- End of picture text -----

Financial review and statements 41

Stakeholder engagement – s.172 statement

The Health Foundation's board recognises the critical importance of its relationships with our key stakeholders to achieve its mission of building a healthier UK. To achieve our mission we need build and maintain collaborative relationships with a wide range of stakeholders.

National government, policymakers

We build evidence by conducting, commissioning and mobilising the highest quality research and analysis. We use this evidence – and our independence – to shape policy and practice by influencing and working with people working within national, regional and local government.

Examples from 2025 : The year saw the launch of our NHS Productivity Commission, in recognition of the vital need to improve productivity in the health service. The commission’s first major report drew on over 100 important submissions from key organisations, NHS staff and service users. In May, our analysis on the cost of digitising the NHS and adult social care helped to inform the thinking behind the £10bn committed for digitisation in the Spending Review, with a senior official telling us it had ‘helped to shift thinking at the Treasury’.

People working across the health, care and wider system

We encourage long-term thinking and work with stakeholders including health and care organisations, other public services, investors, businesses and communities. We use our evidence, insights to promote improvements to health and other public services. We encourage and spread innovation and support new initiatives where a large-scale, long-term focus is needed to make a difference and lead networks for service improvement and learning.

42 Financial review and statements

Examples from 2025 : The Q Community exceeded 6,000 members, delivered its first paid-for board development offer and secured funding to support the NHS in Wales to implement quality management systems. Our Adopting Innovation programme funded an early adopter of the ‘Brazilian’ Community Health and Wellbeing Worker model – a community-led approach designed to bridge the gap between clinical health care and local neighbourhoods. This was instrumental in the government’s commitment to the model in the 10-Year Health Plan: the programme in Cornwall and academic evaluation of our funded project was cited by Wes Streeting to justify the focus on this approach.

Our beneficiaries

The Foundation's beneficiaries include the public, people working across the health and care system, researchers and academics and organisations receiving grants. To maximise the impact of our work we share our evidence across employs various communication channels such as webinars, podcasts, publications, blogs, newsletters, and social media. We aim to maximise the effectiveness of supported programmes and projects by managing our awards. We build skills, knowledge and capability by supporting people and organisations, including through, partnerships, fellowship programmes, networks and events.

Examples from 2025 : Health Equals continued to champion action on health inequality, with its cross-sector coalition of member organisations more than doubling to 105. Its award-winning ‘Hazmat Loungewear’ public campaign brought attention to the health risks from damp, cold and mouldy homes. In October, the Foundation’s flagship AI in the NHS Summit convened NHS and industry leaders to explore and share best practice in testing and spreading impactful AI solutions.

Our employees

Our employees’ skills, experience and understanding of our strategy are key for delivering our mission. We aim to create an inclusive and diverse organisation with high employee satisfaction and motivation and where people are supported to develop and grow. We have in place approaches for wellbeing, health and safety, support for staff-led peer networks, a people forum, an EDI strategy and action plan and comprehensive learning and development programmes. In July 2025 we also formally recognised UNISON as our trade union.

Financial review and statements 43

Examples from 2025 : We engaged in a variety of ways and ran a series of focus groups with colleagues across the Foundation to develop our values and behaviours framework. At the Colleagues Conference in June, we took the opportunity to listen to people’s feedback on some of the early emerging themes. Following this, we refined the values and identified the behaviours to each of the values, to get to a final framework which represents how we want to be perceived, and the types of behaviours expected. Our new values are Impact, Evidence, Integrity, and Collaboration and they help us to stay aligned with our mission, reflect who we are and what we believe, and they will guide all that we do.

Our partners and other advocates

Through sharing what we learn and collaborating with others, we aim to make a difference and contribute to a healthier population. We engage with others working in health and on the wider determinants of health, meeting regularly across levels of seniority to share ideas and working together on pieces of work to maximise impact.

Examples from 2025 : Our independent Commission for Healthier Working Lives published its final report, setting out clear recommendations on how to improve the health of the working-age population, which continues to influence national policy. We welcomed the seventh cohort of Sciana fellows to our European leadership programme focused on cross-cutting challenges facing health and care in Europe. We also published a mix of work comparing international health systems to identify lessons for policy in the UK – including a major new report with OECD.

Suppliers

The Foundation engages a range of suppliers, including investment managers, to support the delivery of its charitable objectives. Suppliers are expected to operate in accordance with ESG imperatives, to align with the Foundation’s commitment to equity, diversity and inclusion, and to deliver demonstrable value for money in both services and/or associated impact. As an accredited Living Wage employer, the Foundation seeks to promote fair pay practices within its supply chain, including the payment of at least the Living Wage for labour provided.

44 Financial review and statements

Highlights for 2025 : During the year, the Funding, Procurement and Partnerships function was restructured to support delivery of the Foundation’s Strategy 2030. This included the adoption of a more centralised model for the strategic management of third-party related activities. As a result, we have strengthened our systems, data capability and reporting, and enhanced the Foundation’s ability to monitor performance, manage risk and support informed decision-making. These enhancements are enabling more active and timely supplier management, supporting stronger performance oversight and enhanced value for money.

Risk management

The Foundation set out its approach to managing risk, including roles and responsibilities, in its risk management policy. The Audit and Risk Committee and the board of governors regularly review key risks owned by members of the senior leadership team.

The Audit and Risk Committee give direction and reviews the implementation of the risk management process supported by an internal audit plan. Detailed below were the most important risks for 2025.

Key risk Nature of risk Management of risk
Investment
risk
The value of our
endowment is reduced
by a significant,
sustained drop in the
equities market and/
or poor investment
decisions, resulting in
insufficient funds for the
charitable activities.
Executive accountability for the endowment sits with
the Chief Investment Officer (CIO), who operates
within clearly defined delegated authority. Investment
oversight is delegated to the Investment Committee,
which meets quarterly and comprises a majority of
members with specialist expertise in investment
strategy and global asset markets, ensuring informed
challenge and effective scrutiny. Every 3 years,
supported by professional advisers, a full Strategic
Asset Allocation review is undertaken to assess
whether the balance between targeted returns and the
associated level of investment risk remains appropriate
and sustainable. While the portfolio is predominantly
invested in long‑term equity assets to provide inflation
protection, it also maintains strongliquidity.
Strategic
relevance
We fail to address the
biggest issues facing
health and care in the
UK and we struggle to
respond to emerging
issues, limiting our
impact and influence.
Robust oversight arrangements are in place to
support delivery of Strategy 2030. The strategy has
been approved by the Board following a thorough
development process. Since its establishment in
January 2025, the Strategy Committee has become an
effective mechanism for scrutinising and challenging
new work, identifying emerging issues, and guiding
priorities. In addition, the creation of a new Strategic
Opportunities Unit will help embed ongoing horizon
scanning and strengthen the integration of strategic
insight into future planning.

Financial review and statements 45

Key risk Nature of risk Management of risk
Data,
technology
and cyber
governance
Inadequate governance
of data, technology
and cyber security
results in fragmented
systems, inconsistent
data, weakened
control environments,
and increased
exposure to cyber
threats, undermining
organisational
resilience, assurance,
and decision‑making.
Cyber risk is continuously monitored through
dedicated security oversight mechanisms. An
enterprise IT strategy is being developed to address
system fragmentation and improve data coherence
across the organisation. The strategy will strengthen
accountability and governance for technology and data,
establishing consistent oversight of systems, suppliers,
and assurance evidence. Enhanced governance
will improve auditability, reduce technology risk,
and underpin robust cyber and information security
controls.
Change
management
The Future Foundation
Programme fails to
deliver the planned
benefits, resulting in
failure to materialise
opportunities to align to
its strategy and improve
operational efficiency.
The scope of the change management programme has
largely stabilised, and a new organisational structure
is in place to support delivery of Strategy 2030. While
this represents important progress, further process and
operational changes are required to fully embed the
new operating model. There remains a risk that capacity
constraints or change fatigue could affect delivery and
benefits realisation. Clear, timely communication and
sustained support for staff therefore remain critical to
mitigating these risks and ensuring successful adoption
of the remainingchanges.
People,
culture and
capability
Failure to build a
cohesive culture,
maintain staff
engagement, and
secure the right
balance of skills and
independent expertise
at board, executive,
and operational levels
thereby weakening
leadership capacity and
impairing delivery of the
Foundation’s strategy.
Good progress has been made in implementing
the People Plan, with focused delivery across the
four priority projects: Leadership and Management;
Values and Behaviours; Progression and Reward; and
the Equality, Diversity and Inclusion (EDI) Strategy.
These initiatives will strengthen leadership capability,
cultural alignment, and staff engagement in support
of the Foundation’s strategic objectives. In parallel,
succession planning arrangements for the Board of
Governors, Executive Committee, and other critical
roles are being developed to address capability and
resilience risks and ensure continuity of leadership and
expertise.
Quality Our work lacks
sufficient rigour,
accuracy, quality
and objectivity
with associated
reputational damage.
A governance framework for both funded and in‑house
research was approved by the Foundation’s Executive
Committee. We also have in place a quality assurance
policy and process which applies to all published
analysis undertaken in‑house.

Compliance and other corporate risks are important to the Foundation, and our internal audit strategy helps manage both. Through this we ensure all risks on our corporate risk register are covered in a 3–4-year cycle.

The internal audit annual report opinion remains at the second highest rating which has been renamed in the year to ‘generally satisfactory with improvements required in some areas’. This opinion is based on the outcomes of internal audit reviews completed during the year which assessed the design and operating effectiveness of controls across key risk areas. These continued to reflect that while there is further work to be done, in the main we

46 Financial review and statements

are now operating in an environment where there are appropriate procedures and controls in place to mitigate the key risks, accepting that there are ongoing opportunities to improve their efficiency and effectiveness.

This aligns with the conclusions of work on our assurance map in June 2025, which provides an overview of the key assurance mechanisms in place across the Foundation. The conclusion of the second full review of the map was that: ‘The Foundation has made significant improvements to its assurance structures in comparison to those observed during the last assurance mapping exercise in 2022.’ This reflects a more mature and coordinated approach to risk management and assurance.

Financial review and statements 47

Trustees’ report

Structure, governance and management

The Health Foundation is a registered charity and a company limited by guarantee. It is governed by its memorandum and articles of association adopted on 24 July 1996 and last amended on 15 July 2021. The Foundation’s endowment was first established in 1998.

The board is responsible for the overall governance of the Foundation. All governors are members and directors of the company, and trustees of the registered charity. Governors are appointed for a term of 5 years and may be appointed for a second term of up to 4 years. The current governors and any past governors who served during the year are listed in the table below, together with the names of independent members of committees.

Name Member/
governor
Audit
Committee
Investment
Committee
Programme related
investments
committee (from
November 2025)
Remuneration
and
Governance
Committee
Hugh Taylor Chair (until end
July 2025)
David Behan
(appointed
9 July 2025)*
Chair (from
1 August 2025)
Katie Blacklock Chair
Dawn Edge
Kim Graham (from
16 August
2025)
Eric Gregory (until 30
June 2025)
Chair (until
30 June
2025)
Chair (until 30 June
2025)
(until 30
June 2025)
Ravi Gurumurthy (until
31 August
2025)
(until 31 August
2025)
Loraine Hawkins
Ruth Hussey Vice Chair Chair
Paul Najsarek Chair (from
1 July 2025)
Karen Reid (from
12 August
2025)
(from
18 September
2025)
Roland Sinker

48 Financial review and statements

Name Member/
governor
Audit
Committee
Investment
Committee
Programme related
investments
committee (from
November 2025)
Remuneration
and
Governance
Committee
David Smart** Chair (from
1 April 2026)
Rosalind Smyth (until 17 July
2025)
(until 17 July
2025)
Rachel Sylvester
Stian Westlake (from
12 August
2025)
(from
6 October
2025)

**David Smart was engaged by the Foundation as a paid Investment Consultant from 31 October 2024 until 31 March 2026. Arrangements were in line with the Foundation’s Policy on Payments to Governors Providing Contracted Services and followed the Charity Commission’s guidance on payments for trustees.

The following served as independent members of committees during 2025.

Name Audit Committee Investment Committee
Robert Beveridge (until June 2025)
Mark Chaloner
Andrew Milligan

The board regularly reviews the skills and experience of the governors to ensure they are relevant to the Foundation’s mission and provide balance to the board.

The board meets at least four times a year and approves strategic, business plans and budgets and reviews operational and investment performance.

All new governors receive a comprehensive induction. Refresher sessions on relevant topics are arranged for governors periodically and the board reviews

Financial review and statements 49

its governor training and development policy every 2 years. The articles of association set a minimum number of trustees at 5 and a maximum at 15.

Organisational structure and how decisions are made

The board of governors has set down a schedule of matters which it cannot delegate in line with the Charity Commission guidance on matters reserved for board decision. These include:

In addition, the following are established as committees of the board of the Foundation in accordance with the articles of association. Each operates in accordance with terms of reference, which ensures the committee is properly constituted with an appropriate membership of governors and experienced independent members as needed and a clear set of responsibilities and authorities.

50 Financial review and statements

The Foundation has three subsidiary companies:

Financial review and statements 51

the limited partner, is entitled to all investment returns less a priority share by the general partner.

The board of governors delegates the exercise of certain powers in connection with the management and administration of the Foundation to the leadership team managed by the chief executive.

Senior leadership

The chief executive is responsible for the day-to-day management of the Foundation’s affairs and for implementing policies agreed by the board of governors. The chief executive is assisted by a group of senior leaders who are listed below. Although the senior executive team are called directors, they are not the ‘legal’ directors of the charitable company.

Chief Executive Jennifer Dixon
Chief Operating Officer (until March 2026),
ManagingDirector (from April 2026)
Nick Bateson
Chief Investment Officer* Alex Schoenfeldt (from February 2026)
Director of Communications Patrick South
Director of Health Jo Bibby (until May 2026)
Director of Innovation and Improvement Malte Gerhold (until September 2025)
Director of Policy (until August 2025)
Director of Policy and Research (from
September 2025)
Hugh Alderwick
Director of Research and Analysis Charles Tallack (until August 2025)
Interim Director of Analysis Carl Mayers (from September 2025 to
January 2026)
Director of Analysis Daniel Law (from February 2026)

*The Chief Investment Officer role has been covered by Nick Bateson until February 2026, with David Smart stepping down as Chair of Investment committee and acting as a consultant until 31 March 2026.

52 Financial review and statements

The charity’s registered office and list of key advisers can be found in legal and administrative information (page 27).

Principal activities and development

The Health Foundation is an independent charitable organisation working to build a healthier UK. It achieves this through supporting people and organisations. Further information on the charity’s activities and developments are included in the Strategic report.

Statement of governors’ responsibilities

The governors are responsible for the preparation of the annual report, including the strategic report and governors’ report, and the financial statements in accordance with applicable law and UK Generally Accepted Accounting Practice. Company law requires the governors to prepare financial statements for each financial year that give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable group for that period.

In preparing these financial statements, the governors are required to:

The governors have overall responsibility for ensuring that the Foundation has appropriate systems and controls, financial and otherwise. They are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the Foundation and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets

Financial review and statements 53

of the Foundation and for their proper application as required by charity law, and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reasonable assurance that:

Each of the governors has confirmed that as far as they are aware, there is no relevant audit information of which the Foundation’s auditors are unaware. The governors have each taken all the steps necessary in order to make themselves aware of any relevant audit information and to establish that the Foundation’s auditors are aware of that information.

Processes are in place to ensure that management information is prepared and reviewed regularly by both the directors’ team and the board of governors. Internal controls over all forms of commitment and expenditure continue to be refined to improve efficiency.

The systems of internal control are designed to provide reasonable but not absolute assurance against material misstatement or loss. They include:

54 Financial review and statements

Declarations and conflicts of interest policy

The Foundation has drawn up and implemented a declarations of interest policy that explains the nature of potential conflicts of interest. It requires governors, independent members of committees, employees and other defined categories of individual with whom the Foundation works from time to time, to declare all interests relevant to the Foundation’s work and provides a framework for managing situations when conflicts arise.

Governors, independent members of committees and senior employees are also required to notify the chief executive or chief operating officer of any association with a body or organisation which is or might become an applicant for funds from the Foundation. A register is kept and those interests declared by governors and members of the directors’ team are reviewed regularly by the directors and produced for inspection at all board meetings.

Details of transactions with related parties are set out in note 25 of the financial statements. The Foundation has a comprehensive whistle-blowing policy.

None of the governors has any beneficial interest in the company. All the governors are members of the company and guarantee to contribute £1 in the event of a winding up.

This Trustees’ report, including Strategic report, prepared under the Charities Act 2011 and the Companies Act 2006, was approved by the governors on 16 July 2026 in their capacities as trustees of the charity and directors of the company. This included their approval of the Trustees’ and strategic reports contained within it. The Trustees’ report is signed as authorised on their behalf by:

Sir David Behan, Chair 16 July 2026

Financial review and statements 55

Independent auditor’s report to the members of the Health Foundation

Opinion

We have audited the financial statements of The Health Foundation (the ‘parent charitable company’) and its subsidiaries (the ‘group’) for the year ended 31 December 2025, which comprise the Consolidated Statement of Financial Activities, the Consolidated Balance Sheet, the Charity Balance Sheet, the Consolidated Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant

56 Financial review and statements

to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statement is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group or parent charitable company’s ability to continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the financial statements. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Financial review and statements 57

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

Matters on which we are required to report

by exception

In the light of the knowledge and understanding of the group and the parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the trustees’ report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

58 Financial review and statements

Responsibilities of trustees

As explained more fully in the trustees’ responsibilities statement set out on pp 53–4, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group’s and the parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Based on our understanding of the group and the industry in which it operates, we identified that the principal risks of non-compliance with laws and regulations related to the acts by the group, which were contrary to applicable laws and regulations including fraud, and we considered the

Financial review and statements 59

extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Companies Act 2006, the Charities Act 2011, FRS 102 and the Charities SORP 2019. We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related posting manual journal entries to manipulate financial results, management bias through judgements and assumptions in significant accounting estimates, in particular in relation to investment valuations and the grants payable.

Our audit procedures were designed to respond to those identified risks, including non-compliance with laws and regulations (irregularities) and fraud that are material to the financial statements. Our audit procedures included but were not limited to:

Our audit procedures in relation to fraud included but were not limited to:

60 Financial review and statements

There are inherent limitations in the audit procedures described above and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Colin Wright (Senior Statutory Auditor)

For and on behalf of UHY Hacker Young

Chartered Accountants and Statutory Auditor

4 Thomas More Square London E1W 1YW

Financial review and statements 61

Financial statements

Consolidated statement of financial activities for the year ended 31 December 2025

Notes Notes Unrestricted
fund
£’000
Restricted
fund
£’000
Non
Controlling
Interest
(NCI) fund
£’000
Expendable
Endowment
fund
£’000
Total
2025
£’000
Total
2024
£’000
Income:
Charitable
activities
3 799 406 – – 1,205 2,339
Investment
income
4 20,964 – – – 20,964 14,864
Capital applied
to income
5 33,837 – – (33,837) – –
Total income 55,600 406 – (33,837) 22,169 17,203
Expenditure:
Fund
management
6 – – – 13,069 13,069 16,857
Charitable
activities
7 55,600 896 – – 56,496 50,427
Total resources
expended
55,600 896 – 13,069 69,565 67,284
Operating
(deficit)/surplus
– (490) – (46,906) (47,396) (50,081)
Net gain/(loss)
on investments
11 – – – 82,563 82,563 103,821
Net (expenditure)/income
for the year before
transfers
– (490) – 35,657 35,167 53,740
Transfers
between funds
– 40 – (40) – –
Net income/(expenditure)
for the year before NCI
– (450) – 35,617 35,167 53,740
NCI income/
(expenditure)
for the year
– – (444) – (444) (551)
Net income/(expenditure)
for the year
– (450) (444) 35,617 34,723 53,189
Fund balances
as at 1 January
– 450 (438) 1,228,248 1,228,260 1,175,071
Fund balances as at
31 December
– – (882) 1,263,865 1,262,983 1,228,260

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure is derived from continuing activities. For the full comparatives see note 28.

62 Financial review and statements

Consolidated balance sheet as at 31 December 2025

Notes Notes 2025
£’000
£’000
2025
£’000
£’000
2024
£’000
£’000
2024
£’000
£’000
Fixed assets:
Intangible fixed assets 12 56 539
Tangible fixed assets 13 1,725 2,256
Investments 14 1,279,746 1,242,010
Programme‑related investment 14 526 526
Total fixed assets 1,282,053 1,245,331
Current assets:
Debtors 16 1,491 1,355
Cash and short‑term deposits 5,274 5,033
Total current assets 6,765 6,388
Current liabilities:
Amounts falling due within one year 17 (10,803) (13,695)
Net current liabilities (4,038) (7,307)
Total assets less current liabilities 1,278,015 1,238,024
Creditors: amounts falling due after
more than one year
18 (11,840) (9,066)
Provisions for liabilities 20 (3,192) (698)
Net assets 1,262,983 1,228,260
Capital funds
Endowment funds general 1,263,865 1,228,248
Income funds
Unrestricted fund – –
Restricted funds – 450
Total funds before NCI 1,263,865 1,228,698
Non Controlling Interest (NCI)
funds
NCI fund (882) (438)
Total funds 1,262,983 1,228,260

The accounts were approved by the governors, and authorised for issue on 17 July 2026 and signed by:

Sir David Behan

Trustee

Paul Najsarek

Trustee

Company Registration No. 01714937

Financial review and statements 63

Charity balance sheet as at 31 December 2025

Notes Notes 2025
£’000
£’000
2025
£’000
£’000
2024
£’000
£’000
2024
£’000
£’000
Fixed assets:
Intangible fixed assets 12 56 134
Tangible fixed assets 13 1,725 2,235
Investments 14 924,246 847,295
Programme‑related investment 14 356,026 396,663
Total fixed assets 1,282,053 1,246,327
Current assets:
Debtors 16 1,168 1,109
Cash and short‑term deposits 4,239 4,035
Total current assets 5,407 5,144
Current liabilities:
Amounts falling due within one year 17 (10,705) (13,618)
Net current liabilities (5,298) (8,474)
Total assets less current liabilities 1,276,755 1,237,853
Creditors: amounts falling due after
more than one year
18 (11,840) (9,066)
Provisions for liabilities 20 (3,193) (698)
Net assets 1,261,722 1,228,089
Capital funds
Endowment funds general 1,261,722 1,227,639
Income funds
Unrestricted fund – –
Restricted funds – 450
Total funds 1,261,722 1,228,089

The company has taken advantage of the legal dispensation granted under s.408 of the Companies Act 2006 allowing it not to present its own statement of financial activities. The company’s net income for the year is £33,633k (2024: net income £53,149k).

The accounts were approved by the governors, and authorised for issue on 17 July 2026 and signed by:

Sir David Behan

Trustee

Paul Najsarek Trustee

Company Registration No. 01714937

64 Financial review and statements

Consolidated statement of cash flows for the year ended 31 December 2025

Notes Notes 2025
£’000
£’000
2025
£’000
£’000
2024
£’000
£’000
2024
£’000
£’000
Cash flows from operating
activities:
Cash absorbed by operations 27 (52,435) (58,524)
Investment activities:
Purchase of tangible fixed assets (46) (161)
Investment proceeds re‑invested (20,444) (14,246)
Withdrawals from investments 65,271 72,535
Investment management fees (13,069) (16,857)
Investment income 20,964 14,864
Net cash generated from
investing activities
52,676 56,135
Net increase/(decrease) in cash and
cash equivalents
241 (2,389)
Cash and cash equivalents at
beginningof year
5,033 7,422
Cash and cash equivalents at end
of year
5,274 5,033

Financial review and statements 65

Notes to the financial

statements for the year

ended 31 December 2025

Charity information

The Health Foundation is a private company limited by guarantee incorporated in England and Wales. The registered office is 8 Salisbury Square, London EC4Y 8AP.

The liability of the governors in their capacity as members of the company is limited. Each member guarantees any deficiency in the Foundation to a maximum of £1.

1.0 Accounting policies

1.1 Accounting convention

These accounts have been prepared in accordance with The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), Accounting and Reporting by Charities, the Statement of Recommended Practice for charities applying FRS 102, the Companies Act 2006 and UK Generally Accepted Accounting Practice. The Foundation is a Public Benefit Entity as defined by FRS 102.

The accounts are prepared in sterling, which is the functional currency of the Foundation. Monetary amounts in these financial statements are rounded to the nearest £’000.

The accounts have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Basis for consolidation

The financial statements consolidate the charity and its wholly owned subsidiary entities, The Victoria Fund LP Incorporated, Medtrust Innovations Limited and THIS Labs Ltd.

66 Financial review and statements

The charitable company has taken advantage of the exemptions in FRS 102 not to present a company only cash flow statement and certain disclosures about the company’s financial instruments. The company has taken advantage of the legal dispensation granted under s.408 of the Companies Act 2006 allowing it not to present its own statement of financial activities. The company’s net income for the year is £33,634k (2024: net income £53,149k).

1.3 Going concern

At the time of approving the financial statements, the governors have a reasonable expectation that the Foundation has adequate resources to continue in operational existence for the foreseeable future. This expectation includes an assessment of the ongoing impact of political and economic challenges facing global markets. There is market uncertainty which may lead to some volatility. We have enough liquidity in the portfolio to fund the charity’s plans for the foreseeable future. Under our normal internal governance procedures, we conducted a Strategic Asset Allocation review in 2024 and continue to monitor this in light of ongoing uncertainties. Thus, the governors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.4 Charitable funds

The Foundation maintains three types of funds: unrestricted funds, restricted funds and expendable endowment funds. Income and expenditure on these funds are shown separately in the statement of the financial activities.

Unrestricted funds are available for use at the discretion of the governors in furtherance of their charitable objectives unless the funds have been designated for other purposes. The income is made up of investment income, other incoming resources and any capital applied as income.

Restricted funds are subject to specific conditions as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the accounts.

Expendable endowment funds represent capital gifted for the long-term benefit of the Foundation. Any income arising from the Endowment fund assets is added to the unrestricted fund. The trustees may also, at their discretion, determine to apply part or all of the endowment capital as income at which time the relevant amounts are transferred to the unrestricted fund.

Financial review and statements 67

1.5 Incoming resources

Income is recognised when dividends and interest are receivable and includes recoverable taxation. Income received but not distributed by pooled funds is included as part of the net gains on investments in the statement of financial activities.

1.6 Resources expended

Expenditure is recognised on an accruals basis. Irrecoverable VAT is included within the expense items to which it relates.

Expenditure on raising funds represents amounts paid to the Foundation’s external investment advisers and custodian, and an apportionment of internal support costs based on time spent. They are charged to the endowment fund, as the primary role of the investment managers and the custodian is to safeguard the investment assets of the Foundation.

Charitable activities comprise all costs incurred in the pursuit of charitable objects. These are:

68 Financial review and statements

which the contributions are paid. Provision is made for the discounted expected future costs of unfunded pension benefit commitments at each balance sheet date, based on actuarial advice.

1.7 Intangible fixed assets other than goodwill

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

Intangible assets are defined as having finite useful lives and the costs are amortised on a straight-line basis over the term of the project life. Intangible assets are stated at cost less amortisation and are reviewed for impairment whenever there is an indication that the carrying value may be impaired.

1.8 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses. Tangible fixed assets with a value over £5,000 are capitalised. Depreciation is recognised to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset and is recognised in net income/(expenditure) for the year.

1.9 Fixed asset investments

Fixed asset investments comprise both quoted and unquoted investments and are initially measured at transaction price, excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

Financial review and statements 69

Quoted investments are listed shares, bonds and units and are stated at fair value on the basis equivalent to market value using the bid price. Asset sales and purchases are recognised at the date of trade.

Unquoted investments are stated at fair value based on professional valuations at the balance sheet date or nearest available date to it. For hedge funds, the valuations are provided by third-party hedge fund administrators. In the case of private equity funds, there is no readily identifiable market price. These funds are included at the most recent valuations by their respective managers. Investments made shortly before the balance sheet date are held at cost where the managers have yet to provide a valuation.

A subsidiary is an entity controlled by the Foundation. Control is the power to govern the financial and operating policies of the entity to obtain benefits from its activities. Subsidiaries are included in the Foundation’s balance sheet at their net asset value which represents the fair value of their underlying investments and other net assets. Investments in subsidiary undertakings are held at cost less any impairment.

Unrealised gains and losses are recognised at the year-end as the difference between the historical cost and the market value of the investment assets. Realised gains and losses are recognised during the year at the time the investment is sold, and include any fees incurred at source. All unrealised and realised gains and losses on investments are included within the statement of financial activities.

1.10 Impairment of fixed assets

Impairment of tangible and intangible fixed assets are reviewed annually and any impairment is recognised as an expense in the year that it occurs.

1.11 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of 3 months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

70 Financial review and statements

1.12 Financial instruments

The Foundation has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Foundation’s balance sheet when the Foundation becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within 1 year are not amortised.

Basic financial liabilities

Basic financial liabilities, including trade creditors and grants payable are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Financial liabilities classified as payable within 1 year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within 1 year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial review and statements 71

Derecognition of financial liabilities

Financial liabilities are derecognised when the Foundation’s contractual obligations expire or are discharged or cancelled.

1.13 Provisions and grants

Provisions and grants are recognised when the Foundation has a legal or constructive present obligation as a result of a past event, it is probable that the Foundation will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting end date, taking into account the risks and uncertainties surrounding the obligation.

Where the effect of the time value of money is material, the amount expected to be required to settle the obligation is recognised at present value. When a provision or grant is measured at present value the unwinding of the discount is recognised as a finance cost or grant expense in net income/(expenditure) in the period it arises.

1.14 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the Foundation is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.15 Retirement benefits

Retirement pensions and related benefits to defined contribution schemes are charged to the unrestricted fund in the accounting year in which the contributions are paid.

1.16 Leases

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight-line basis over the term of the relevant lease.

72 Financial review and statements

1.17 Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in net income/expenditure for the period.

1.18 Exemptions

The charitable company has taken advantage of the exemptions in FRS 102 not to present a company only cash flow statement and certain disclosures about the company’s financial instruments. The company has taken advantage of the legal dispensation granted under s.408 of the Companies Act 2006 allowing it not to present its own statement of financial activities. The company’s net income for the year is £33,634k (2024: net income £53,149k).

2.0 Critical accounting estimates and judgements

In the application of the Foundation’s accounting policies, the governors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are outlined below:

Financial review and statements 73

Investment valuation

The Foundation’s investments are stated at market value. Fixed asset investments comprise both quoted and unquoted investments and are initially measured at transaction price, excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred. Valuations are obtained from the investment managers. The governors do not believe that there is any inherent uncertainty in the presentation of these amounts, and that in their judgement, market value and fair value may be regarded as identical for the purposes of these accounts.

3.0 Charitable activities

Share of profit
in_BMJ Quality_
& Safety
£’000
THIS Labs Ltd
£’000
Other income
£’000
Total
2025
£’000
Total
2024
£’000
Other income* 298 301 606 1,205 2,339
Analysis by funds:
Unrestricted funds 298 301 200 799
Restricted funds – – 406 1,205
298 301 606 1,205
For year ended
31 December 2024:
Unrestricted funds 280 175 160 615
Restricted funds – – 1.724 1,724
280 175 1,884 2,339

*In 2025, we received restricted income of £406k (2024: £1,724k) mainly from NHS England for Q, a jointly funded initiative.

4.0 Investments

4.0
Investments
2025
£’000
2024
£’000
Income from listed investments 10,986 9,521
Fixed interest income 7,514 2,009
Property fund income 2,275 3,463
Alternatives income 189 (129)
20,964 14,864

The increase in alternatives income was a result of a slowed exit environment after a period of high interest rates in 2024.

74 Financial review and statements

5.0 Capital applied to income

Unrestricted
funds
£’000
Endowment
funds
general
£’000
Total
2025
£’000
Total
2024
£’000
Released from endowment
funds
33,837 (33,837) – –
For the year ended
31 December 2024
33,016 (33,016) – –

6.0 Fund management

6.0
Fund management
2025
£’000
2024
£’000
Cost of fund management:
Investment advisory costs 394 344
Staff and operating costs 860 666
Custodian fees 114 78
Investment managers’ fees 11,701 15,769
13,069 16,857

The investment managers’ fees of £11,701k (2024: £15,769k) includes: management fees of £8,391k (2024: £9,464k), incurred on the endowment value of £1,279,746k (2024: £1,242,010k) and performance fees of £1,759k (2024: £5,261k), the decrease is driven by a large performance fee relating to a private equity distribution in 2024.

The cost of raising funds is 1.0% (2024: 1.4%).

Financial review and statements 75

7.0 Expenditure on charitable activities

Effective
innovation and
improvement
in health and
care
£’000
Better health
and care
policy making
£’000
Improving
health and
reducing
inequalities
£’000
Cross‑cutting
strategic
activities
£’000
Total
2025
£’000
Total
2024
£’000
Grant
funding of
activities
(see note 29)
11,567 5,057 3,632 909 21,165 16,497
Direct costs* 12,332 4,012 2,881 1,004 20,229 21,253
Share of
support
costs*
7,710 3,371 2,421 606 14,108 11,955
Share of
governance
costs*
543 237 171 43 994 722
32,152 12,677 9,105 2,562 56,496 50,427

*See note 8

Analysis by
fund:
Unrestricted
funds
31,256 12,677 9,105 2,562 55,600 48,495
Restricted
funds
896 – – – 896 1,932
32,152 12,677 9,105 2,562 56,496 50,427

2025 was the final year of our 3 year strategy and the above table reflects the three strategic priorities for 2023–5.

For the year ended 31 December 2024

Unrestricted
funds
Restricted
funds
Effective
innovation and
improvement
in health
and care
£’000




Better health
and care
policy making
£’000



Improving
health and
reducing
inequalities
£’000



Cross‑cutting
strategic
activities
£’000



Total
£’000
24,563 5,208 14,111 4,613 48,495
1,932 –
–
– 1,932
26,495 5,208 14,111 4,613 50,427

76 Financial review and statements

8.0 Direct, support and governance costs

Direct costs
£’000
Support costs
£’000
Governance
costs
£’000
2025
£’000
2024
£’000
Staff costs 16,064 7,279 611 23,954 20,232
Depreciation – 633 – 633 1,163
Property costs – 1,825 – 1,825 1,794
Technology
costs
217 1,532 – 1,749 2,173
Other direct/
support costs
3,948 2,574 – 6,522 8,164
Audit fees – 13 74 87 71
Legal and
professional
– 237 106 343 196
Internal audit – 15 75 90 93
Other
governance
costs
– – 128 128 44
20,229 14,108 994 35,331 33,930

Direct costs of charitable activities are mainly to further the Foundation’s objectives by organising conference and events, carrying out direct and commissioned work in-house, scoping, developing, and managing grant programmes, and publishing and disseminating reports on research findings.

Support costs have been allocated to charitable activities in the year.

Governance costs include payments to auditors of £87k (2024: £71k) for audit fees and £5k (2024: £8k) for non-audit services.

9.0 Governors

David Smart has acted as an investment consultant to the Investment team from October 2024, temporarily stepping down from his role as Investment Committee Chair. Interim Investment Committee Chair is Katie Blacklock. David was recompensed £259k in 2025 (2024: £60k).

None of the other governors (or any persons connected with them) received any remuneration or benefits from the Foundation during the year.

Trustees’ expenses received totalled £261k (2024: £63k), including the investment consultant fees paid to David Smart.

Financial review and statements 77

10.0 Employment costs

10.0
Employment costs
2025
£’000
2024
£’000
Wages and salaries 20,076 17,123
Social security costs 2,294 1,938
Other pension costs 1,844 1,617
Other costs 47 9
Total employment costs* 24,261 20,687

*Total employment costs during the year were £24,261k (2024: £20,687k). This includes salary costs relating to management of the endowment of £307k (2024: £455k) and are included in cost of raising funds (note 6) rather than note 8.

The wages and salaries in 2025 includes a £2.4m provision for redundancy given the collective consultation that started in November 2025, excluding this the increase reflects usual cost of living changes.

The average number of employees during the year was 281 (2024: 273), noting the headcount was higher until end of October (an average of 286), and then decreased with the transfer of the Q team to their new home in NHS Alliance (renamed NHS Confederation) resulting in an average headcount in November and December of 260. This equated to a full time equivalent of 262 (2024: 254), decreasing to 238 in December after the Q team transfer.

78 Financial review and statements

The number of employees whose overall remuneration in the year was £60,000 or more were (note the calculation includes salary, compensation, NI and employers pension contributions):

and employers pension contributions):
2025 2024
£60,001–£70,000 35 46
£70,001–£80,000 56 29
£80,001–£90,000 14 16
£90,001–£100,000 19 10
£100,001–£110,000 1 8
£110,001–£120,000 12 7
£120,001–£130,000 3 4
£130,001–£140,000 2 1
£140,001–£150,000 2 1
£150,001–£160,000 2 1
£160,001–£170,000 – 1
£170,001–£180,000 1 1
£180,001–£190,000 1 1
£200,001–£210,000 – 1
£210,001–£220,000 – 1
£220,001–£230,000 1 –
£280,001–£290,000 – 1
£290,001–£300,000 2 –

Financial review and statements 79

11.0 Net gain/(loss) on investments

11.0
Net gain/(loss) on investments
2025
£’000
2024
£’000
Revaluation of investments 82,563 103,821

Net revaluation of investments comprises:

12.0 Intangible fixed assets

Group Software
£’000
Q Project
£’000
Total
£’000
Cost:
At 1 January 2025 1,597 2,186 3,783
Write offs (535) – (535)
At 31 December 2025 1,062 2,186 3,248
Amortisation and impairment:
At 1 January 2025 1,058 2,186 3,244
Amortisation charge in the year 128 – 128
Write offs (180) – (180)
At 31 December 2025 1,006 2,186 3,192
Carrying amount:
At 31 December 2025 56 – 56
At 31 December 2024 539 – 539

Software relates to (i) our key office applications, including finance and grant management systems, and Microsoft Office 365 applications; (ii) our secure data environment.

The write offs were for consultancy costs relating to software installations (£61k) which was fully depreciated and to write off the THIS Labs intangible assets (£475k) which included a write down of £119k as it was not yet fully depreciated.

80 Financial review and statements

12.0 Intangible fixed assets (continued)

The Q Initiative identifies and connects people skilled in improvement across the UK, through online and events-based capabilities that promote knowledge-sharing, development, and other improvement activities. The Q team transferred to NHS Alliance (renamed NHS Confederation) in November 2025 but given the changes in NHS Alliance the IT infrastructure has not been fully transferred, this will be completed and then written off in 2026.

Charity Software
£’000
Q Project
£’000
Total
£’000
Cost:
At 1 January 2025 1,123 2,186 3,309
Write offs (61) – (61)
At 31 December 2025 1,062 2,186 3,248
Amortisation and impairment:
At 1 January 2025 989 2,186 3,175
Amortisation charge in the year 78 – 78
Write offs (61) – (61)
At 31 December 2025 1,006 2,186 3,192
Carrying amount:
At 31 December 2025 56 – 56
At 31 December 2024 134 – 134

Financial review and statements 81

13.0 Tangible fixed assets

----- Start of picture text -----
Group Fixtures and Computer Total
fittings equipment
£’000 £’000 £’000
Cost:
At 1 January 2025 5,405 809 6,214
Additions 11 35 46
Write offs – (232) (232)
At 31 December 2025 5,416 612 6,028
Depreciation and impairment:
At 1 January 2025 3,310 648 3,958
Depreciation charge in the year 460 111 571
Write offs – (226) (226)
At 31 December 2025 3,770 533 4,303
Carrying amount:
At 31 December 2025 1,646 79 1,725
At 31 December 2024 2,095 161 2,256
Charity Fixtures and Computer Total
fittings equipment
£’000 £’000 £’000
Cost:
At 1 January 2025 5,405 777 6,182
Additions 11 35 46
Write offs – (200) (200)
At 31 December 2025 5,416 612 6,028
Depreciation and impairment:
At 1 January 2025 3,310 637 3,947
Depreciation charge in the year 460 96 556
Write offs – (200) (200)
At 31 December 2025 3,770 533 4,303
Carrying amount:
At 31 December 2025 1,646 79 1,725
At 31 December 2024 2,095 140 2,235
----- End of picture text -----

82 Financial review and statements

14.0 Fixed assets investments

14.0 Fixed assets investments 14.0 Fixed assets investments 14.0 Fixed assets investments
Investments
Group Portfolio
£’000
Other
£’000
Total
£’000
Valuation:
At 1 January 2025 1,242,010 526 1,242,536
Valuation changes 81,131 – 81,131
Income (excluding bank interest) 20,424 – 20,424
Investment management costs included in the
fund
(10,222) – (10,222)
Net withdrawals from portfolio (53,597) – (53,597)
At 31 December 2025 1,279,746 526 1,280,272
Cost:
At 31 December 2025 1,191,578 526 1,192,104
At 31 December 2024 1,139,632 526 1,140,158
Notes 2025
£’000
2024
£’000
Other investments comprise:
Programme‑related investments 26 526 526
Investments at fair value comprise:
Property funds 51,675 63,875
Infrastructure funds 76,059 66,591
Equities 657,565 661,774
Fixed interest 184,734 92,675
Alternatives 256,746 312,450
Impact 8,171 2,599
Cash 44,796 42,046
1,279,746 1,242,010

Financial review and statements 83

14.0 Fixed assets investments (continued)

Investments Investments Investments
Charity Portfolio
£’000
Other
£’000
Total
£’000
Valuation:
At 1 January 2025 847,295 396,663 1,243,958
Valuation changes 62,921 15,290 78,211
Income 15,839 4,585 20,424
Investment management costs included in the
fund
(1,612) (8,610) (10,222)
New funds contributed to the portfolio – 1,500 1,500
Funds withdrawn from portfolio (197) (53,402) (53,599)
At 31 December 2025 924,246 356,026 1,280,272
Cost:
At 31 December 2025 900,223 291,881 1,192,104
At 31 December 2024 839,893 300,265 1,140,158
Notes 2025
£’000
2024
£’000
Other investments comprise:
Investment in subsidiaries 355,500 396,136
Programme‑related investments 526 526
Investment in subsidiaries 26 356,026 396,662
Investments at fair value comprise:
Property funds 51,675 63,876
Equities 657,565 661,774
Fixed interest 184,734 92,675
Alternatives 8,171 2,161
Cash 22,101 26,809
924,246 847,295

A currency hedging programme was in place during the year to manage foreign currency exchange risk. At 31 December 2025, the group had open foreign exchange forward contracts, to mitigate any currency risk between USD and Sterling on the hedge fund mandate in the Victoria Fund. These contracts have been revalued at the applicable year-end revaluation rate, and the resulting unrealised gains/(losses) are included within the overall value of the investments above.

84 Financial review and statements

14.0 Fixed assets investments (continued)

At 31 December 2025, the Victoria Fund held contracts to buy £136,292k and $13,807k at fixed rates (2024: £225,604k and $41,024k). The unrealised loss associated with these forward currency contracts totalled £2,325k as at 31 December 2025 (2024: £4,051k loss).

The Victoria Fund’s underlying hedge fund investments provide varying degrees of liquidity based on their own redemption terms, which typically begin with an initial lock-up period. These investments are made on an ongoing basis. As a result, the Victoria Fund may not be able to liquidate all its investments quickly. As investment lock-up periods ease in future periods, more short-term liquidity is expected.

The following table illustrates the expected liquidity of assets and liabilities held as at 31 December 2025:

Less than
6 months
£’000
6–12
months
£’000
More than
12 months
£’000
Long‑term
lock up*
£’000
Total non‑current assets – – – 316,930
Total current assets 41,422 – – –
Total current liabilities (2,670) – – –

*This relates to underlying funds in the Victoria Fund, whose redemptions have been locked up and private equity funds which have no redemption opportunities.

At the balance sheet date, the Foundation had total unfunded investment commitments of £136,876k (2024: £148,660k) for private equity and infrastructure from total commitments of £475,745k (2024: £463,495k). These commitments form part of the planned asset allocation and will be met from within the existing endowment investments. Included in these numbers are the directly held impact investments.

In September 2024 £4m was committed to Meridian Health Ventures Fund I Limited Partnership to date capital of £3.1m has been called (2024: £2.6m). This venture fund invests in UK companies across digital health, med-tech and enterprise software primarily in the UK, seeking to improve patient outcomes as well as the lives of healthcare workers in the UK and beyond. In December 2024 $10m was committed JP Morgan Campbell global forestry and climate solutions fund II, to date capital of $5.1m has been called (2024: $0m).

Financial review and statements 85

15.0 Financial instruments

15.0
Financial instruments
Group 2025
£’000
2024
£’000
Carrying amount of financial assets:
Debt instruments measured at amortised cost 5,686 5,297
Instruments measured at fair value through profit or loss 1,279,746 1,242,010
Carrying amount of financial liabilities:
Measured at amortised cost 22,643 22,761
Charity 2025
£’000
2024
£’000
Carrying amount of financial assets:
Debt instruments measured at amortised cost 4,328 4,053
Instruments measured at fair value through profit or loss 924,246 847,295
Carrying amount of financial liabilities:
Measured at amortised cost 27,819 27,717

16.0 Debtors: Amounts falling due within 1 year

Group Group Charity Charity
2025
£’000
2024
£’000
2025
£’000
2024
£’000
Other debtors 412 264 75 4
Prepayments and
accrued income
1,079 1,091 1,079 1,091
Amounts due from subsidiaries – – 14 14
1,491 1,355 1,168 1,109

86 Financial review and statements

17.0 Creditors: Amounts falling due within 1 year

Group Group Charity Charity
2025
£’000
2024
£’000
2025
£’000
2024
£’000
Trade creditors 920 617 822 540
Grants payable 7,513 9,806 7,513 9,806
Other creditors 955 1,419 955 1,419
Accruals and deferred income 1,415 1,853 1,415 1,853
10,803 13,695 10,705 13,618

18.0 Creditors: Amounts falling due after more than 1 year

Group Group Charity Charity
2025
£’000
2024
£’000
2025
£’000
2024
£’000
Grants payable – in 2 to 5 years 11,840 9,066 11,840 9,066

19.0 Grants payable

19.0 Grants payable
2025
£’000
2024
£’000
As at 1 January 18,872 29,090
Grants committed in the year 13,951 16,127
Paid during the year (13,401) (26,809)
Discounting applied to grants payable in more than a year (69) 464
As at 31 December 19,353 18,872
Split into:
Grants payable – due within 1 year (note 17) 7,513 9,806
Grants payable – in 2 to 5 years (note 18) 11,840 9,066
As at 31 December 19,353 18,872

Financial review and statements 87

20.0 Provisions for liabilities

20.0 Provisions for liabilities 20.0 Provisions for liabilities 20.0 Provisions for liabilities
2025
£’000
2024
£’000
Pension obligations 423 411
Dilapidations 349 287
Redundancy and related costs 2,420 –
3,192 698
Movement on provisions:
Pension
obligations
£’000
Dilapidations
£’000
Redundancy &
related costs
£’000
Total
£’000
At 1 January 2025 411 287 – 698
Increase/(decrease) in the year 39 62 2,420 2,521
Payment in the year (27) – – (27)
At 31 December 2025 423 349 2,420 3,192

21.0 Retirement benefit schemes

a) AEGON Group Personal Pension Plan

The Health Foundation offers all current employees the opportunity to join the defined contribution Group Personal Pension Plan provided by AEGON. Contributions in the year were £1,817k (2024: £1,590k). There was £70k in outstanding contributions at 31 December 2025 (2024: £6k).

b) Other retirement benefits

The Foundation has an unfunded future commitment to a former employee. The contractual commitment (as defined in the contractual arrangement) is to pay a pension equivalent to 1/60th of their pensionable salary for each year of pensionable service less any amounts of pension paid to the same members under The Pensions Trust Growth Plan. The potential pension liability at 31 December 2025, based on advice from an actuary, is estimated to be £423k (2024: £411k).

88 Financial review and statements

22.0 Analysis of net assets between funds

Group Unrestricted
fund
£’000
Restricted
fund
£’000
Non
Controlling
Interest
fund
£’000
Expendable
Endowment
fund
£’000
Total
£’000
Fund balances at 31 December 2025 are represented by:
Intangible
fixed assets
56 – – – 56
Tangible
assets
1,725 – – – 1,725
Programme
related
526 – – – 526
Investments 16,289 – – 1,263,457 1,279,746
Current
(liabilities)/
assets
(3,564) – (882) 408 (4,038)
Long term
liabilities
(11,840) – – – (11,840)
Provisions (3,192) – – – (3,192)
– – (882) 1,263,865 1,262,983
Charity Unrestricted
fund
£’000
Restricted
fund
£’000
Non
Controlling
Interest
fund
£’000
Expendable
Endowment
fund
£’000
Total
£’000
Fund balances at 31 December 2025 are represented by:
Intangible
fixed assets
56 – – – 56
Tangible
assets
1,725 – – – 1,725
Investments 18,958 – – 905,288 924,246
Investment in
subsidiary
– – – 356,026 356,026
Current
(liabilities)/
assets
(5,706) – – 408 (5,298)
Long term
liabilities
(11,840) – – – (11,840)
Provisions (3,193) – – – (3,193)
– – – 1,261,722 1,261,722

Financial review and statements 89

23.0 Capital commitments

The Foundation has a number of contracts that have been entered into, but which are not disclosed as liabilities as they are severable. They cover technical support for our award holders, evaluation and operational services. They are recognised on a cash basis as and when the expenditure is incurred. These amounted to £12,533k at 31 December 2025 (2024: £12,715k).

24.0 Financial commitments

At 31 December 2025, the company had a property lease for its office premises that expires in September 2028. The future minimum lease payments are as follows:

Land and buildings Land and buildings Machinery Machinery
2025
£’000
2024
£’000
2025
£’000
2024
£’000
Expiry date:
Within 1 year 1,650 1,650 47 23
Between 2 and 5 years 2,889 4,539 59 –
Over 5 years – – – –

25.0 Related party transactions

David Smart has been engaged by the Foundation as a paid Investment Consultant since 31 October 2024. Arrangements are in line with the Foundation’s Policy on Payments to Governors Providing Contracted Services (last reviewed by the board in July 2024) and follows the Charity Commission’s guidance on payments for trustees.

Due to the specialist nature of the projects funded, circumstances may occasionally arise where governors, committee members or staff are associated with organisations which apply for grants. In such cases, the Foundation has clear policies and procedures to ensure that the governor, committee member or member of staff is not involved in the assessment or approval of the grant. All such transactions are undertaken on an arm’s-length basis in accordance with the normal grant assessment and arrangements. Details of governors and senior management who have interests in organisations to which the Foundation has made awards or contracted within 2025 are noted in the table below.

90 Financial review and statements

25.0 Related party transactions (continued)

Board member/
senior management
Role in associated organisation Associated organisation
Paul Najsarek Board member
(until September 2024)
What Works Centre for Wellbeing
Hugh Taylor Trustee Cicely Saunders International
Mark Chaloner Investment Committee member British Red Cross

During the year, Victoria Fund LP Incorporated, a subsidiary of the Foundation, received no investment contributions from the charity (2024: £0). Medtrust Innovations Limited, a subsidiary of the Foundation, donated its profit of £188k (2024: £168k) to the Foundation. In April 2025 the Foundation invested a further £1.5m as a Convertible Loan Note into THIS Labs.

Remuneration of key management personnel

Key management personnel are considered to be the chief executive officer and others as set out in the senior management section of the governors’ annual report. Total remuneration of this group in the year, was as follows:

2025
£’000
2024
£’000
Key management personnel 1,488 1,652

Financial review and statements 91

26.0 Subsidiaries

The Foundation had three subsidiary undertakings and the details at 31 December 2025 are as follows:

Name of undertaking Registered office Nature of
business
Class of shares
held
% Held Direct
Indirect
Medtrust Innovations
Limited
England and
Wales
Intellectual
property
Ordinary 100.00
The Victoria Fund LP
Incorporated
Guernsey Investment fund
vehicle
– –
THISLabs Limited England and
Wales
Business and
domestic
software
development
Ordinary A 70.17

Medtrust Innovations Limited (Medtrust)

Medtrust is wholly owned by the Foundation and is a company registered in England and Wales. It is engaged in the exploitation of intellectual property rights with the same registered office as the Foundation: 8 Salisbury Square, London, EC4Y 8AP.

In March 2011, the Foundation purchased 524,998 ordinary shares of Medtrust at £1 each to finance an investment to acquire 50% of the intellectual property rights of BMJ Quality & Safety, a journal published by the BMJ Publishing Group Limited. This social motive investment is held at cost in the charity balance sheet. Medtrust undertakes an impairment review each year.

At 31 December 2025, Medtrust had fixed assets of £526k (2024: £526k) and net current assets of £188k (2024: £168k). The shareholders’ funds include called-up share capital of £526k (2024: £526k) and reserves of £188k (2024: £168k).

During the year, Medtrust had an operating profit of £188k (2024: £168k). The sum equivalent to its taxable profits will be donated to the Foundation, as provided for in Medtrust’s Articles of Association.

92 Financial review and statements

26.0 Subsidiaries (continued)

The Victoria Fund LP Incorporated (Victoria Fund)

The Victoria Fund was formed in February 2010 and is a limited partnership, number 1275, registered in Guernsey. It is a vehicle to invest in a combination of hedge funds, private equity and private infrastructure, with a registered office of Oak House, Hirzel Street, St. Peter Port, Guernsey, GY1 2NP.

The limited partner is the Health Foundation and the general partner is Brook Street Limited, a Cayman Islands exempt limited company. Brook Street has delegated its powers to an investment manager, Cambridge Associates Limited.

The Health Foundation as the limited partner is entitled to all investment returns less a priority share by the general partner (Brook Street Limited) from the Victoria Fund and, for consolidation purposes, it is treated as a wholly owned subsidiary of the Foundation.

As at 31 December 2025, the Victoria Fund had net investment assets of £354, 834k (2024: £388,411k) and the value of its net assets was £355,682k (2024: £394,891k). Net profit in the year was £14,900k (2024: £22,537k).

THIS Labs Ltd (THIS Labs)

THIS Labs is a private limited company and a 70.12% owned subsidiary of the Health Foundation, incorporated in November 2022 and began trading in May 2023. In April 2025 the Foundation invested a further £1.5m as a Convertible Loan Note into THIS Labs. THIS Labs was created to drive innovation and improved approaches to engagement in research and consultation projects. The registered office is Burnham House, Splash Lane, Wyton, PE28 2AF.

At 31 December 2025, THIS Labs (renamed Thiscovery Ltd in January 2026) had fixed assets of £362k (2024: £423k) and net current assets of £1,069k (2024: £977), with long term creditors of £1,500k (2024: £0k) due to the credit loan note. The shareholders’ funds include called-up share capital of £1k (2024: £1k) and reserve liabilities of £68k (2024: £1,420k reserve assets).

In 2025 THIS Labs had an operating loss of £1,489k (2024: £1,839k).

Financial review and statements 93

26.0 Subsidiaries (continued)

The original investment in THIS Labs by the non-controlling interest had a asset value of £0.5m for 29.83% of the company. This included the intellectual property associated with the proprietary software. Due to the accumulated losses to date, the non-controlling interest’s share of those losses is a deficit of £882k (2024: £438k), which has been shown within equity in the Foundation accounts. The non-controlling interest deficit is not a cause for concern as it was expected as part of the start-up phase of the company and recent revisions to the strategy and structure of the business have significantly reduced the cost base. In the Health Foundation accounts given the deficit position the value of THIS Labs has been written off and on consolidation at the group level we have written off the value of the fixed assets (£0.4m).

27.0 Cash used by operations – Group

27.0 Cash used by operations – Group
2025
£’000
2024
£’000
Surplus for the year 34,723 53,189
Adjustments for:
Investment income recognised in profit or loss (20,964) (14,864)
Cost of raising funds 13,069 16,857
Fair value (gains) and losses on investments (82,563) (103,821)
Depreciation, amortisation and impairment of fixed assets 1,060 1,214
Movements in working capital:
(Increase)/decrease in debtors (136) 121
Decrease in creditors (118) (11,289)
Increase in provisions 2,494 69
Cash absorbed by operations (52,435) (58,524)

94 Financial review and statements

28.0 Comparative consolidated statement of financial activities for the year ended 31 December 2024

Notes Notes Unrestricted
fund
£’000
Restricted
fund
£’000
Non
controlling
Interest
(NCI) fund
£’000
Expendable
Endowment
fund
£’000
Total
2024
£’000
Income:
Charitable activities 3 615 1,724 – – 2,339
Investments 4 14,864 – – – 14,864
Capital applied to
income
5 33,016 – – (33,016) –
Total income 48,495 1,724 – (33,016) 17,203
Expenditure:
Fund management 6 – – – 16,857 16,857
Charitable activities 7 48,495 1,932 – – 50,427
Total resources
expended
48,495 1,932 – 16,857 67,284
Operating profit/
(deficit)
– (208) – (49,873) (50,081)
Net gain on
investments
11 – – – 103,821 103,821
Net income/
(expenditure) for the
year before NCI
(208) – 53,948 53,740
NCI income/
(expenditure) for
the year
– – (551) – (551)
Net income/
(expenditure) for the
year
– (208) (551) 53,948 53,189
Fund balances as at
1 January 2024
658 113 1,174,300 1,175,071
Fund balances as at
31 December 2024
– 450 (438) 1,228,248 1,228,260

Financial review and statements 95

29.0 Grant funding

The Foundation funded £21,165k of grants in 2025 (2024: £16,497k). These grants range from small one-off awards to multi-year demonstration projects and fellowships. Integral to all our award making is direct support from the Foundation, as well as expertise from technical providers and consultants. This support is organised and paid for by the Foundation, delivered directly to the award holders and can be in the form of technical development and assistance, learning events and coaching. Within this grant funding the Foundation also funds research and external evaluations to ensure programmes are evidence-based and offer value for money.

Grants made to organisations and individuals are analysed by strategic objective in the table below:

objective in the table below:
Lead recipient for strategic priority: Supporting radical innovation and improvement
in health and care services
Total £
NHS Confederation 7,282,000
Organisation for Economic Co‑operation and Development (OECD) 50,000
Guys and St Thomas NHS Foundation Trust 39,800
Staffordshire University 36,400
Midlands and Lancashire Commissioning Support Unit 28,700
NHS Midlands and Lancashire Commissioning Support Unit – The Strategy Unit 25,000
One HealthTech 22,000
Somerset NHS Foundation Trust 20,000
Royal College of Anaesthetists 20,000
Oxford University Hospitals NHS Foundation Trust 20,000
NHS Hampshire and Isle of Wight ICB 20,000
Bradford District & Craven ICB 20,000
North West Anglia NHS Foundation Trust 20,000
Homerton Healthcare NHS Trust 20,000
Humber & North Yorkshire ICB 19,800
COPE Scotland 19,400
Health Innovation West of England 17,600
SDSmyhealthcare 17,400
Hertfordshire and West Essex ICB 5,200
Sheffield Digestive Diseases 5,000
Queen’s University Belfast (600)
University of Cambridge Department of Public Health and Primary Care (2,200)
Norfolk and Norwich University Hospitals NHS Foundation Trust (4,100)

96 Financial review and statements

29.0 Grant funding (continued)

----- Start of picture text -----
Lead recipient for strategic priority: Supporting radical innovation and improvement
Total £
in health and care services (continued)
Lancashire Teaching Hospitals NHS Foundation Trust (9,800)
The University of Manchester (10,100)
Bradford Teaching Hospitals NHS Foundation Trust (13,300)
Total 7,668,100
Lead recipient for strategic priority: Providing evidence and analysis to improve
Total £
health and care policy
University of York 3,187,600
Organisation for Economic Co‑operation and Development (OECD) 61,100
University of Manchester 17,000
London School of Economics 16,500
The Commonwealth Fund 5,900
Brown University School of Public Health (32,300)
Total 3,255,800
Lead recipient for strategic priority: Improving people’s health and
Total £
reducing inequalities
Caribbean & African Health Network (CAHN) 250,000
The Chartered Institute of Public Finance and Accountancy (CIPFA) 130,500
West Midlands Combined Authority 56,000
Race Equality Foundation 49,200
Global Action Plan 30,000
The Innovation Unit 30,000
Centre for Mental Health 30,000
Royal Society of Wildlife Trusts 29,800
Food Foundation 29,300
Liverpool City Region Combined Authority (3,800)
University of Cambridge Department of Public Health and Primary Care (10,400)
Leeds City Council (12,500)
Local Government Association (LGA) (17,800)
Resolution Foundation (26,100)
Total 564,200
----- End of picture text -----

Financial review and statements 97

29.0 Grant funding (continued)

----- Start of picture text -----
Lead recipient for strategic priority: Cross cutting strategic activities Total £
Queen Mary University of London 4,200
Centre for Health Communication Research (CHCR) Enterprises Limited (9,600)
Total (5,400)
Lead recipient for strategic priority: Supporting radical innovation and improvement
7,668,100
in health and care services
Lead recipient for strategic priority: Providing evidence and analysis to improve
3,255,800
health and care policy
Lead recipient for strategic priority: Improving people's health and
564,200
reducing inequalities
Lead recipient for strategic priority: Cross cutting strategic activities (5,400)
Grants and donations awarded to charities by governors 218,800
Movement in discounting of grants payable in more than a year (69,400)
Services provided by third parties to support award holders and further the work of
9,532,600
the Foundation
Total grants 21,164,600
----- End of picture text -----

98 Financial review and statements

Appendix: Directly held investment fund managers

Aikya Investment Management Pinnacle Investment Management Octagon Point 5, Cheapside, London, EC2V 6AA United Kingdom

Axiom Investors 33 Benedict Place Greenwich, CT 06830 United States of America

BlackRock Investment Management Ltd 12 Throgmorton Avenue London, EC2N 2DL United Kingdom

Impax Asset Management Ireland Limited The Lennox Building Richmond Street South Dublin 2, D02 FK02 Ireland

J.P. Morgan Campbell Global 10 South Dearborn Street, Suite 1400 Chicago, IL 60603 United States of America Legal & General Investment Management One Coleman Street London, EC2R 5AA United Kingdom

Meridian Health Ventures 75–79 York Road London, SE1 7NJ United Kingdom

Ninety One 25 Basinghall Street London, EC2V 5HA United Kingdom

Ownership Capital Herengracht 105–107 1015BE Amsterdam The Netherlands

Savills Investment Management LLP 33 Margaret Street London, W1G 0JD United Kingdom

Schroders Investment Management 1 London Wall Place London, EC2Y 5AU United Kingdom

Swiss Life 55 Wells Street London, W1T 3PT United Kingdom

TwentyFour Asset Management 8th Floor, The Monument Building 11 Monument Street London, EC3R 8AF United Kingdom

Financial review and statements 99

The Health Foundation is an independent charitable organisation working to build a healthier UK.

Health is our most precious asset. Good health enables us to live happy, fulfilling lives, fuels our prosperity and helps build a stronger society.

Yet good health remains out of reach for too many people in the UK and services are struggling to provide access to timely, high-quality care. It doesn’t have to be like this.

Our mission is to help build a healthier UK by:

We will achieve this by generating research and analysis, testing practical solutions, bringing people together through convening and partnerships, and developing networks and long-term capability.

Keep up to date

TheHealthFoundation

@HealthFoundation

@TheHealthFoundation

The Health Foundation

8 Salisbury Square, London EC4Y 8AP 020 7257 8000 info@health.org.uk

© 2026 The Health Foundation

Registered charity number: 286967 Registered company number: 01714937

Financial review and statements

101